SCHEMBL22729462

SCHEMBL22729462

Cc1cn(-c2ccccc2)c(=O)c2c(C=O)cn(C)c12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.39
IMPDH2 P12268 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
BRD4 O60885 1/20 0.38
KDM4E B2RXH2 4/20 0.36
CYP1A2 P05177 1/20 0.36
HPGD P15428 1/20 0.36
BLM P54132 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
POLB P06746 1/20 0.35
THRB P10828 1/20 0.35
PKM P14618 1/20 0.35
RECQL P46063 1/20 0.35
RAB9A P51151 1/20 0.35
TSHR P16473 1/20 0.35
ATM Q13315 1/20 0.34
MAPT P10636 3/20 0.33
MAPK1 P28482 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22729442 0.80 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2KDM4ECYP1A2HPGD
SCHEMBL22729797 0.79 ALDH1A1 (0.36) ALDH1A1IMPDH2BRD4KDM4ETSHR
SCHEMBL22729500 0.78 KDM4E (0.49) ALDH1A1BRD4KDM4ECYP1A2HPGD
SCHEMBL22729483 0.72 RAB9A (0.48) ALDH1A1SMN1; SMN2HPGDMEN1KMT2A
SCHEMBL14519092 0.72 ALDH1A1 (0.42) ALDH1A1IMPDH2SMN1; SMN2BRD4KDM4E
SCHEMBL22729836 0.71 KDM4E (0.43) ALDH1A1BRD4KDM4ECYP1A2HPGD
SCHEMBL22729607 0.69 BRD4 (0.47) ALDH1A1BRD4HPGDLMNA
SCHEMBL22729399 0.67 CNR2 (0.50) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL25294091 0.64 SMN1; SMN2 (0.47) ALDH1A1SMN1; SMN2KDM4ECYP1A2HPGD
SCHEMBL5858717 0.64 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2KDM4ECYP1A2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11459325-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-10-04 US disclosed
US-20210087186-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-03-25 US disclosed
EP-3747885-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2020-12-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210087186-A1 HETEROCYCLIC COMPOUND GBA1, GBA2, GALC ALDH1A1 2626/4885IMPDH2 2154/4885SMN1; SMN2 151/4885
US-11459325-B2 Heterocyclic compound GBA1, GBA2, GALC ALDH1A1 2660/4885IMPDH2 2129/4885SMN1; SMN2 155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.